Structure Therapeutics’ (GPCR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note released on Friday morning, Benzinga reports. The firm currently has a $65.00 target price on the stock.

Separately, Lifesci Capital reiterated an outperform rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $85.71.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $39.74 on Friday. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The stock’s 50 day moving average price is $39.32 and its two-hundred day moving average price is $46.50. The stock has a market capitalization of $1.85 billion and a price-to-earnings ratio of -47.88.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. On average, equities research analysts forecast that Structure Therapeutics will post -0.98 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GPCR. TD Asset Management Inc raised its position in Structure Therapeutics by 109.3% in the 3rd quarter. TD Asset Management Inc now owns 152,176 shares of the company’s stock valued at $7,673,000 after buying an additional 79,467 shares during the last quarter. Jennison Associates LLC increased its position in shares of Structure Therapeutics by 5.2% during the 3rd quarter. Jennison Associates LLC now owns 420,479 shares of the company’s stock valued at $21,201,000 after purchasing an additional 20,699 shares during the last quarter. Platinum Investment Management Ltd. increased its position in shares of Structure Therapeutics by 249.7% during the 3rd quarter. Platinum Investment Management Ltd. now owns 52,461 shares of the company’s stock valued at $2,645,000 after purchasing an additional 37,461 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Structure Therapeutics during the 3rd quarter valued at $7,611,000. Finally, Picton Mahoney Asset Management purchased a new stake in shares of Structure Therapeutics during the 3rd quarter valued at $116,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.